What is agtc?
Founded in 1999, AGTC operates as a specialized clinical-stage biotechnology firm dedicated to the development of transformative gene-based therapies. The company distinguishes itself through a robust, proprietary platform designed to address severe, rare diseases that have historically lacked effective treatment options. By focusing on ocular health, AGTC occupies a critical niche in the life sciences market, bridging the gap between foundational genetic research and commercial-ready therapeutic applications. Their operational model emphasizes rigorous clinical validation, ensuring that their pipeline remains aligned with evolving regulatory standards and patient requirements in the ophthalmology space.
How much funding has agtc raised?
agtc has raised a total of $124.5M across 2 funding rounds:
Stock Offering
$50M
Stock Offering
$74.5M
Stock Issuance/Offering (2014): $50M, investors not publicly disclosed
Stock Issuance/Offering (2021): $74.5M, investors not publicly disclosed
Key Investors in agtc
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for agtc?
With the recent influx of capital, AGTC is well-positioned to accelerate its clinical development programs and expand its research capabilities. The strategic deployment of these funds will likely focus on scaling manufacturing processes and advancing late-stage clinical trials, which are essential for regulatory approval and eventual market entry. As the company transitions further into its growth phase, the focus will shift toward optimizing its therapeutic delivery mechanisms and exploring potential partnerships to enhance its commercial reach. Investors and industry stakeholders will be monitoring the firm's ability to translate its genetic research into scalable, patient-centric solutions that address the complexities of severe ophthalmic diseases.
See full agtc company page
